Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization, and Mortality
Copyright © 2021 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved..
BACKGROUND: It remains unclear if patients with allergic rhinitis (AR) and/or asthma are susceptible to corona virus disease 2019 (COVID-19) infection, severity, and mortality.
OBJECTIVE: To investigate the role of AR and/or asthma in COVID-19 infection, severity, and mortality, and assess whether long-term AR and/or asthma medications affected the outcomes of COVID-19.
METHODS: Demographic and clinical data of 70,557 adult participants completed SARS-CoV-2 testing between March 16 and December 31, 2020, in the UK Biobank were analyzed. The rates of COVID-19 infection, hospitalization, and mortality in relation to pre-existing AR and/or asthma were assessed based on adjusted generalized linear models. We further analyzed the impact of long-term AR and/or asthma medications on the risk of COVID-19 hospitalization and mortality.
RESULTS: Patients with AR of all ages had lower positive rates of SARS-CoV-2 tests (relative risk [RR]: 0.75, 95% confidence interval [CI]: 0.69-0.81, P < .001), with lower susceptibility in males (RR: 0.74, 95% CI: 0.65-0.85, P < .001) than females (RR: 0.8, 95% CI: 0.72-0.9, P < .001). However, similar effects of asthma against COVID-19 hospitalization were only major in participants aged <65 (RR: 0.93, 95% CI: 0.86-1, P = .044) instead of elderlies. In contrast, patients with asthma tested positively had higher risk of hospitalization (RR: 1.42, 95% CI: 1.32-1.54, P < .001). Neither AR nor asthma had an impact on COVID-19 mortality. None of conventional medications for AR or asthma, for example, antihistamines, corticosteroids, or β2 adrenoceptor agonists, showed association with COVID-19 infection or severity.
CONCLUSION: AR (all ages) and asthma (aged <65) act as protective factors against COVID-19 infection, whereas asthma increases risk for COVID-19 hospitalization. None of the long-term medications had a significant association with infection, severity, and mortality of COVID-19 among patients with AR and/or asthma.
| Errataetall: |
CommentIn: J Allergy Clin Immunol Pract. 2022 Oct;10(10):2777-2778. - PMID 36216467 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
The journal of allergy and clinical immunology. In practice - 10(2022), 1 vom: 01. Jan., Seite 124-133 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ren, Jianjun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allergic rhinitis |
|---|
| Anmerkungen: |
Date Completed 12.01.2022 Date Revised 25.10.2022 published: Print-Electronic CommentIn: J Allergy Clin Immunol Pract. 2022 Oct;10(10):2777-2778. - PMID 36216467 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaip.2021.10.049 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332665801 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332665801 | ||
| 003 | DE-627 | ||
| 005 | 20231225220031.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaip.2021.10.049 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332665801 | ||
| 035 | |a (NLM)34728408 | ||
| 035 | |a (PII)S2213-2198(21)01202-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ren, Jianjun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization, and Mortality |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2022 | ||
| 500 | |a Date Revised 25.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Allergy Clin Immunol Pract. 2022 Oct;10(10):2777-2778. - PMID 36216467 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: It remains unclear if patients with allergic rhinitis (AR) and/or asthma are susceptible to corona virus disease 2019 (COVID-19) infection, severity, and mortality | ||
| 520 | |a OBJECTIVE: To investigate the role of AR and/or asthma in COVID-19 infection, severity, and mortality, and assess whether long-term AR and/or asthma medications affected the outcomes of COVID-19 | ||
| 520 | |a METHODS: Demographic and clinical data of 70,557 adult participants completed SARS-CoV-2 testing between March 16 and December 31, 2020, in the UK Biobank were analyzed. The rates of COVID-19 infection, hospitalization, and mortality in relation to pre-existing AR and/or asthma were assessed based on adjusted generalized linear models. We further analyzed the impact of long-term AR and/or asthma medications on the risk of COVID-19 hospitalization and mortality | ||
| 520 | |a RESULTS: Patients with AR of all ages had lower positive rates of SARS-CoV-2 tests (relative risk [RR]: 0.75, 95% confidence interval [CI]: 0.69-0.81, P < .001), with lower susceptibility in males (RR: 0.74, 95% CI: 0.65-0.85, P < .001) than females (RR: 0.8, 95% CI: 0.72-0.9, P < .001). However, similar effects of asthma against COVID-19 hospitalization were only major in participants aged <65 (RR: 0.93, 95% CI: 0.86-1, P = .044) instead of elderlies. In contrast, patients with asthma tested positively had higher risk of hospitalization (RR: 1.42, 95% CI: 1.32-1.54, P < .001). Neither AR nor asthma had an impact on COVID-19 mortality. None of conventional medications for AR or asthma, for example, antihistamines, corticosteroids, or β2 adrenoceptor agonists, showed association with COVID-19 infection or severity | ||
| 520 | |a CONCLUSION: AR (all ages) and asthma (aged <65) act as protective factors against COVID-19 infection, whereas asthma increases risk for COVID-19 hospitalization. None of the long-term medications had a significant association with infection, severity, and mortality of COVID-19 among patients with AR and/or asthma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Allergic rhinitis | |
| 650 | 4 | |a Asthma | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Glucocorticoids | |
| 650 | 4 | |a Long-term medications | |
| 700 | 1 | |a Pang, Wendu |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Yaxin |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Danni |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Yufang |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yongbo |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Yijun |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Jiajia |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Ying, Zhiye |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Haopeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Xiaoxi |e verfasserin |4 aut | |
| 700 | 1 | |a Zong, Zhiyong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Geoffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Deyun |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of allergy and clinical immunology. In practice |d 2013 |g 10(2022), 1 vom: 01. Jan., Seite 124-133 |w (DE-627)NLM227247523 |x 2213-2201 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:124-133 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaip.2021.10.049 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 1 |b 01 |c 01 |h 124-133 | ||